Preoperative hormone sensitivity test as a tool for personalizing systemic therapy in breast cancer patients

Breast cancer is a heterogeneous disease. Luminal breast cancers account for up to 75 % of all breast cancer cases. However, even within this large group, there are significant differences in the course of the disease and therapeutic response to endocrine therapy, which dictates the need to explore and consider all available biological characteristics of the malignant tumor in optimal treatment decision making. Currently, adjuvant therapy for patients with breast cancer is mainly based on clinical and pathological factors. Multigene signatures that would help in personalizing systemic therapy are currently not available in our country. Therefore, there is a constant search for tools that could effectively predict the effectiveness of endocrine therapy at the early stages of treatment. One of such tools is a preoperative hormone sensitivity test.

1. Bray F., Laversanne M., Sung H. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024;74(3):229–63.

2. Malignant tumors in Russia in 2023 (incidence and mortality). Ed. by A.D. Kaprin, V.V. Starinskiy, A.O. Shakhzadova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2024. 276 p. (In Russ.).

3. Situation with cancer care in Russia in 2024. Ed. by A.D. Kaprin, V.V. Starinskiy, A.O. Shakhzadova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2025. 275 p. (In Russ.).

4. Rossi L., Stevens D., Pierga J. et al. Impact of adjuvant chemotherapy on breast cancer survival: a real-world population. PloS One 2015;10(7):e0132853. DOI: 10.1371/journal.pone.0132853

5. Hara F., Shien T., Iwata H. Prognostic impact of adjuvant endocrine therapy for estrogen receptor-positive and HER2-negative T1a/bN0M0 breast cancer. Breast Cancer Res Treat 2023;202(3):473–83. DOI: 10.1007/s10549-023-07097-6

6. Tyulyandin S.A., Stenina M.B., Frolova M.A. Practical tools to facilitate the choice of adjuvant systemic therapy for resectable luminal HER2-negative breast cancer. Zlokachestvennye opukholi = Malignant Tumors 2024;14(2):51–7. (In Russ.). DOI: 10.18027/2224-5057-2024-003

7. Massagué J. Sorting out breast-cancer gene signatures. N Engl J Med 2007;356(3):294–7. DOI: 10.1056/NEJMe068292

8. Harris L.N., Ismaila N., McShane L.M. et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2016;34(10):1134–50. DOI: 10.1200/JCO.2015.65.2289

9. Duffy M.J., Harbeck N., Nap M. et al. Clinical use of biomarkers in breast cancer: updated guidelines from the European Group on Tumor Markers (EGTM). Eur J Cancer 2017;75:284–98. DOI: 10.1016/j.ejca.2017.01.017

10. Andre F., Ismaila N., Henry N.L. et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: ASCO Clinical Practice Guideline Update – Integration of Results From TAILORx. JCO 2019;37:1956–64. DOI: 10.1200/JCO.19.00945

11. Curigliano G., Burstein H.J., Gnant M. et al. Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023. Ann Oncol 2023;34(11):970–86. DOI: 10.1016/j.annonc.2024.11.001

12. Loibl S., André F., Bachelot T. et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2024;35(2):159–82. DOI: 10.1016/j.annonc.2023.11.016

13. Bartlett J.M., Bayani J., Marshall A. et al. Comparing breast cancer multiparameter tests in the OPTIMA prelim trial: no test is more equal than the others. J Natl Cancer Inst 2016;108(9):1–9. DOI: 10.1093/jnci/djw050

14. Makris A., Powles T., Allred D.C. et al. Changes in hormone receptors and proliferation markers in tamoxifen treated breast cancer patients and the relationship with response. Breast Cancer Res. Treat 1998;48(1):11–20. DOI: 10.1023/a:1005973529921

15. Cuzick J., Dowsett M., Pineda S. et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J Clin Oncol 2011; 29(32):4273–8. DOI: 10.1023/a:1005973529921

16. Dowsett M., Smith I.E., Ebbs S.R. et al. Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clin Cancer Res 2005;11:951–8.

17. Howell A., Harland R.N., Barnes D.M. et al. Endocrine therapy for advanced carcinoma of the breast: relationship between the effect of tamoxifen upon concentrations of progesterone receptor and subsequent response to treatment. Cancer Res 1987;47(1):300–4.

18. ATAC Trialists’ Group, Forbes J.F., Cuzick J. et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008;9(1):45–53. DOI: 10.1016/S1470-2045(07)70385-6

19. DeCensi A., Guerrieri-Gonzaga A., Gandini S. et al. Prognostic significance of Ki-67 labeling index after short-term presurgical tamoxifen in women with ER-positive breast cancer. Ann Oncol 2011;22(3):582–7. DOI: 10.1093/annonc/mdq427

20. Smith I., Robertson J., Kilburn L. et al. Long-term outcome and prognostic value of Ki-67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial. Lancet Oncol 2020;21:1443–54. DOI: 10.1016/S1470-2045(20)30677-X

21. Nitz U., Gluz O., Kümmel S. et al. Endocrine therapy response and 21-gene expression assay for therapy guidance in HR+/HER2– early breast cancer. J Clin Oncol 2022;40:2557–67. DOI: 10.1200/JCO.21.02759